Pelzer U, Sinn M, Stieler J, Riess H
Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Deutschland,
Internist (Berl). 2014 Jan;55(1):31-6. doi: 10.1007/s00108-013-3316-6.
Adenocarcinoma of the exocrine pancreas is one of the most aggressive types of solid tumor and stands at fourth position in the tumor death frequency scale due to a high mortality rate. Effective screening methods are not available and only radical surgery offers a curative option. With adjuvant chemotherapy the median survival time can be prolonged up to 23 months and approximately 25 % of patients are still alive after 5 years. Of these patients approximately 75-80 % are already in a palliative therapy situation at the time of diagnosis. In the last 5 years treatment options have been increased by the introduction of new chemotherapeutic drugs. For patients with metastasized disease median survival times of 6-12 months can currently be achieved depending on the general performance status at diagnosis but less than 5 % of these patients are still alive after 5 years. Neoadjuvant treatment strategies, radiation and immunotherapy do not play a role in evidence-based clinical practice. Despite progress in the understanding of cancer biology and new treatment options, non-resectable adenocarcinoma of the pancreas remains a disease with a very poor prognosis.
胰腺外分泌腺癌是最具侵袭性的实体瘤类型之一，由于死亡率高，在肿瘤死亡频率排行榜上位居第四。目前尚无有效的筛查方法，只有根治性手术提供治愈的可能。辅助化疗可使中位生存时间延长至23个月，约25%的患者在5年后仍存活。在这些患者中，约75% - 80%在诊断时已处于姑息治疗状态。在过去5年中，新化疗药物的引入增加了治疗选择。对于转移性疾病患者，根据诊断时的总体体能状态，目前中位生存时间可达6 - 12个月，但5年后仍存活的患者不到5%。新辅助治疗策略、放疗和免疫疗法在循证临床实践中不起作用。尽管在癌症生物学理解和新治疗选择方面取得了进展，但不可切除的胰腺腺癌仍然是一种预后极差的疾病。
